Uptake of clarithromycin by rat lung cells

Area of Science:

• Pharmacology
• Cell Biology
• Drug Metabolism

Background:

• Macrolide antibiotics like erythromycin and clarithromycin are crucial in treating respiratory infections.
• Understanding drug distribution and tissue affinity is vital for optimizing therapeutic efficacy.
• Previous studies suggest differential tissue penetration among macrolides.

Purpose of the Study:

• To compare the lung tissue affinity of clarithromycin versus erythromycin in vivo and in vitro.
• To elucidate the characteristics and mechanisms underlying clarithromycin uptake by lung cells.
• To investigate potential differences in transport mechanisms between clarithromycin and erythromycin.

Main Methods:

• In vivo administration of radiolabeled clarithromycin and erythromycin to rats, followed by tissue concentration analysis.
• In vitro incubation of isolated rat lung cells with radiolabeled antibiotics.
• Assessment of uptake dependency on cell viability, temperature, ATP, and mitochondrial respiration.
• Kinetic analysis and competitive inhibition studies using clarithromycin analogues.

Main Results:

• Clarithromycin exhibited significantly higher concentrations in rat lung tissue and isolated lung cells compared to erythromycin.
• Uptake by lung cells was an active, energy-dependent process requiring cell viability, optimal temperature, and ATP.
• Clarithromycin uptake was partially dependent on mitochondrial oxidative respiration and showed saturable kinetics.
• Uptake was specifically inhibited by 6-O-methylerythromycin analogues, suggesting a distinct carrier-mediated transport system.

Conclusions:

• Clarithromycin demonstrates superior affinity for lung tissue compared to erythromycin, likely due to a specific carrier-mediated transport system in lung cells.
• This unique transport mechanism for clarithromycin in lung cells contributes to its enhanced accumulation.
• The findings provide insights into the pharmacokinetic differences between clarithromycin and erythromycin, potentially explaining their differential efficacy in lung infections.